A precise measurement is only decisive if the competing possibilities predict different observations. Leucine and isoleucine provide a useful peptide example: they are different residues with the same elemental composition. An intact-mass match cannot distinguish a sequence containing one from an otherwise identical sequence containing the other.
A sequence change with no intact-mass change
In standard residue notation, L denotes leucine and I denotes isoleucine. Waters' electron-capture-dissociation application note explicitly treats them as isomeric residues and demonstrates a specialised way to distinguish their side-chain-related fragmentation.Waters ECD application note (opens in a new tab)
For an original example, compare the hypothetical sequences ALA and AIA, with matching terminal chemistry and no other modifications. Replacing the middle leucine with isoleucine changes the structure while preserving the elemental composition. The two intact peptide masses are therefore the same on the same mass convention.
| Feature | ALA versus AIA |
|---|---|
| Residue count | Unchanged |
| Middle residue identity | Different: L versus I |
| Elemental composition | Unchanged when all other chemistry matches |
| Intact mass | Unchanged on the same mass basis |
| Complete molecular identity | Not established by intact mass alone |
The example does not claim that these two materials were tested or that their biological properties have a particular relationship. It isolates the identity problem: a structural distinction can exist without an intact-mass difference.
Why more decimal places do not solve it
Suppose two candidate structures predict the same exact mass. Improving the agreement between the measured mass and that shared prediction can strengthen the mass assignment, but it cannot choose between those candidates. Both still satisfy the same constraint.
This differs from two candidates with slightly different exact masses that a sufficiently resolving, accurate method might distinguish. Keep the questions separate: are the theoretical values different, and can the actual measurement resolve that difference? With the leucine/isoleucine substitution, the first condition is not met for intact mass.
What additional evidence might help?
The Waters application note uses electron capture dissociation and characteristic w-ion behaviour to assign leucine and isoleucine positions in specific antibody-derived peptides. The demonstrated information comes from a particular fragmentation approach, not just from the intact precursor mass.Waters ECD application note (opens in a new tab)
That makes the example useful in two directions. It shows why “mass spectrometry can never distinguish them” is too broad. It also shows why “LC-MS confirmed the sequence” may be too broad when the actual report gives only an intact-mass match. The claim must follow the evidence generated by the stated method.
A laboratory may use complementary approaches or reference comparisons. Their value depends on whether they genuinely discriminate the candidates under consideration. Do not assume an unreported technique was used simply because it would have been helpful.
Frame the question around the research decision
Imagine a project comparing two sequences differing only at a leucine/isoleucine position. A mass-only certificate could be compatible with either sequence. The unresolved distinction is central to that project, so it belongs in the material-evidence requirements before interpreting the comparison.
In another project, the same ambiguity might not be the only concern or the first one to investigate. The point is not to demand every imaginable test for every sample. It is to identify the alternatives that would change the interpretation and establish what evidence addresses them.
ICH's selectivity guidance provides the general principle: assess interference and discrimination for the intended analytical purpose. A method's capability should be evaluated against that purpose, not treated as a property guaranteed by an instrument acronym.ICH analytical selectivity (opens in a new tab)
Preserve the uncertainty in your conclusion
- State the candidate sequences and the exact difference being assessed.
- Identify which mass observation is shared by those candidates.
- Record any additional diagnostic evidence actually reported.
- If the distinction remains unresolved, describe the identity claim at that narrower level.
For the hypothetical ALA/AIA example, “intact mass is consistent with either candidate” is a precise conclusion. It is more useful than choosing one sequence without evidence, and it does not dismiss the valid information supplied by the mass measurement.
Sources and further detail
- Waters — Biotherapeutic characterisation using electron capture dissociation (opens in a new tab)
Application note 720008287, section on leucine/isoleucine, PDF pages 9–11. A specific demonstrated method, not a claim that every LC-MS assay can distinguish these residues.
- ICH — Q2(R2): Validation of analytical procedures (opens in a new tab)
Section 3.1 and glossary on specificity/selectivity. Used for the question of analytical discrimination, not verification of a Novum method.
Sources checked 19 September 2026. Worked examples are illustrative unless a supplied report is explicitly identified. This article has not undergone independent scientific peer review.